Record Nr. UNINA9910460135303321

Autore Li Robert Y.

Titolo Cardiovascular diseases: from molecular pharmacology to evidence-

based therapeutics / / Y. Robert Li

Pubbl/distr/stampa Hoboken, New Jersey:,: John Wiley & Sons Inc.,, 2015

©2015

ISBN 1-118-88994-0

Descrizione fisica 1 online resource (504 p.)

Disciplina 616.1/061

Soggetti Cardiovascular system - Diseases - Chemotherapy

Cardiovascular system - Diseases - Diagnosis

Electronic books.

Inglese Lingua di pubblicazione

Formato Materiale a stampa

Monografia Livello bibliografico

Note generali Includes index.

Nota di bibliografia Includes bibliographical references and index.

Nota di contenuto Title Page: Copyright Page: Contents: Preface: List of Abbreviations:

> Unit I General Introduction; Chapter 1 Introduction to Cardiovascular Diseases: 1.1 Overview: 1.2 Definition of Cardiovascular Diseases: 1.3 Classification of Cardiovascular Diseases; 1.3.1 Classification Based on Anatomical Location: 1.3.2 Classification Based on the Involvement of Atherosclerosis: 1.3.3 Total Cardiovascular Diseases and ICD-10 Classification: 1.4 Prevalence, Incidence, and Trend of Cardiovascular Diseases; 1.4.1 NCDs and Cardiovascular Diseases: The Global Status 1.4.2 The Status of Cardiovascular Diseases in the United States 1.4.3 The Status of Cardiovascular Diseases in China; 1.5 Risk Factors of Cardiovascular Diseases; 1.5.1 Classification of Cardiovascular Disease Risk Factors: 1.5.2 Major Cardiovascular Disease Risk Factors and Their Impact; 1.6 Prevention and Control of Cardiovascular Diseases; 1.6.1 The UN High-Level Meeting and Tackling Cardiovascular Diseases at the Global Level; 1.6.2 The World Heart Federation Call to Action to Prevent and Control Cardiovascular Diseases

1.6.3 The AHA 2010 Health Impact Goal, 2020 Health Impact Goal, and Ideal Cardiovascular Health1.6.4 US DHSS "Million Hearts" Initiative; 1.7 Cardiovascular Risk Prediction and Evidence-based Treatments; 1.7.1 Cardiovascular Risk Prediction; 1.7.2 Evidence-Based Treatments; 1.8 Summary of Chapter Key Points: 1.9 Self-Assessment Questions:

References; Chapter 2 Introduction to Principles of Pharmacology; 2.1 Overview; 2.2 Definitions and History; 2.2.1 What Is Pharmacology?; 2.2.2 Definitions of Related Terms; 2.2.3 A Brief History of Pharmacology

2.3 Pharmacological Paradigm: the Central Dogma in Pharmacology2. 3.1 Drug Names, Sources, Preparations, and Administration; 2.3.2 Pharmacokinetics; 2.3.3 Pharmacodynamics; 2.3.4 Drug Toxicity; 2.3.5 Pharmacogenetics and Pharmacogenomics; 2.4 Principles of Drug Discovery, Development, and Regulation: 2.4.1 Definitions: 2.4.2 The Paradigm of Drug Creation and Survival; 2.4.3 The FDA Drug Review and Approval Process; 2.5 Pharmacology Subspecialties; 2.6 Introduction to Cardiovascular Pharmacology; 2.6.1 Definition and Scope; 2.6.2 New Developments and Challenges 2.6.3 Systems Pharmacology in the Management of Cardiovascular Diseases2.6.4 Polypill for the Management of Cardiovascular Diseases: 2.6.5 Protein Therapeutics of Cardiovascular Diseases; 2.6.6 Gene Therapy of Cardiovascular Diseases; 2.6.7 Stem Cell Therapy of Cardiovascular Diseases; 2.7 Summary of Chapter Key Points; 2.8 Self-Assessment Questions: References: Unit II Dyslipidemias: Chapter 3 Overview of Dyslipidemias and Drug Therapy; 3.1 Introduction; 3.2 Lipoprotein Metabolism; 3.2.1 Definition, Structure, and Classification of Lipoproteins

3.2.2 Metabolic Pathways of Lipoproteins and Drug Therapy

Sommario/riassunto

Written in an accessible style and consistent format, the book covers both the fundamentals and advances in the pharmacology of cardiovascular drugs, as well as their integrated applications in the management of individual cardiovascular diseases. Integrates fundamentals and recent advances regarding cardiovascular drugs, blending basic and clinical sciences needed to effectively understand and treat cardiovascular diseases Facilitates understanding of drug action and mechanism by covering physiology / pathophysiology and pharmacology Includes guidelines and algorithms for pharmac

2. Record Nr. UNISA996467071403316

Autore TONOLA, Cristina

Titolo Manuale di preparazione alla prima prova orale di diritto amministrativo

: sostanziale e processuale / Cristina Tonola

Pubbl/distr/stampa Piacenza, : La tribuna, 2021

ISBN 978-88-291-0800-8

Descrizione fisica XXXIV, 205 p.; 24 cm

Collana PerCorso nuovo esame avvocato

Disciplina 342.4506076

Soggetti Diritto amministrativo - Italia - Manuali per concorsi

Collocazione XXI.6. 752

XXI.6. 752a

Lingua di pubblicazione Italiano

Formato Materiale a stampa

Livello bibliografico Monografia

Note generali Sul frontespizio: Esame orale rafforzato

3. Record Nr. UNINA9910826443603321 Autore Moreno Badia Marialuz Globalization Drives Strategic Product Switching / / Marialuz Moreno Titolo Badia, Veerle Slootmaekers, Ilke Van Beveren Washington, D.C.:,: International Monetary Fund,, 2008 Pubbl/distr/stampa 1-4623-7092-6 **ISBN** 1-4518-7104-X 9786612841972 1-4527-9649-1 1-282-84197-1 Edizione [1st ed.] Descrizione fisica 1 online resource (68 p.) Collana **IMF** Working Papers IMF working paper; ; WP/08/246 SlootmaekersVeerle Altri autori (Persone) BeverenIlke Van Disciplina 337 Soggetti Globalization - Economic aspects - Estonia - Econometric models Product management - Estonia - Econometric models Costs, Industrial - Estonia - Econometric models **Exports and Imports** Finance: General Industries: Manufacturing Trade: General General Financial Markets: General (includes Measurement and Data) Industry Studies: Manufacturing: General International economics Finance Manufacturing industries **Exports** Commodity markets Competition Manufacturing **Imports** International trade Financial markets Economic sectors

Commodity exchanges Estonia, Republic of

Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references.
Nota di contenuto	Cover Page; Title Page; Copyright Page; Contents; I. Introduction; II. Industry Dynamics in Estonia; 1. Exits and Industry Switches, 1997-2004; 2. Sector Distribution; 3. Four-Digit Product Switches Decomposed25; 4. Destination of Product Switches by Technology Class; III. Determinants of Firm Dynamics; 5. Summary Statistics; A. Firm Characteristics; B. Product Market Characteristics: Domestic Market; C. Product Market Characteristics: International Competition; IV. Results; A. Baseline Results; 6. Baseline Specification; B. Self-Selection into New Markets 7. Product Switching Versus Industry Switching8. Industry Switching: Manufacturing versus Services; 9. Unit Value Difference Between Industry of Origin and Destination; V. Robustness Checks; A. Results by Size Class; 1. Sample Size Distribution; 10. Determinants of Firm Dynamics Across Size Categories; B. Results by Time Period; 11. Determinants of Firm Dynamics Across Time; VI. Conclusions; Appendix I. Data and Sample Selection; Appendix II. Definitions of Variables; Appendix III. Sector Classification According to Technology Intensity and Knowledge; References; Footnotes
Sommario/riassunto	Using firm-level data for Estonia for the years 1997-2005, we analyze the impact of international competition on firm dynamics, considering both firm closedown and product switching. We contribute to the literature in two important ways: (1) this is the first paper to study the determinants of exit and product switching in an emerging market; and (2) we consider explicitly the role of export opportunities. Our results indicate that globalization does not affect firm exit significantly but it is an important factor explaining product switching. Previous studies on industrial countries have shown that product switching has been a defensive strategy against low-cost imports. In contrast, our results suggest that Estonian firms have switched products as an offensive strategy to take advantage of the export opportunities created by trade

liberalization.